TP53 and breast cancer: Selective TM pseudopeptide-mediated Sirt2 inhibition was confirmed by increased acetylation of the Sirt2 substrate α-tubulin and no changes in the acetylation of the Sirt1 substrate p53 in several breast cancer cell lines [186].